What is HC Wainwright’s Forecast for PVLA FY2027 Earnings?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Investment analysts at HC Wainwright cut their FY2027 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a report issued on Monday, October 12th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($13.52) per share for the year, down from their prior estimate of ($7.43). HC Wainwright currently has a “Buy” rating and a $246.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($6.40) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2028 earnings at ($10.40) EPS, FY2029 earnings at ($4.84) EPS and FY2030 earnings at $5.82 EPS.

Several other research firms have also weighed in on PVLA. Chardan Capital assumed coverage on shares of Palvella Therapeutics in a research note on Monday, September 21st. They set a “buy” rating and a $240.00 target price for the company. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. Finally, Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Palvella Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $207.43.

Palvella Therapeutics Stock Down 4.4%

Palvella Therapeutics stock opened at $128.51 on Wednesday. The company has a fifty day moving average price of $147.39 and a two-hundred day moving average price of $134.28. Palvella Therapeutics has a 12 month low of $68.96 and a 12 month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.35).

Insider Activity

In other news, Director George M. Jenkins sold 13,352 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $151.96, for a total transaction of $2,028,969.92. Following the sale, the director directly owned 161,893 shares in the company, valued at approximately $24,601,260.28. This represents a 7.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the sale, the director directly owned 250 shares in the company, valued at approximately $39,250. This trade represents a 55.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 36,417 shares of company stock valued at $5,526,138. 17.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Palvella Therapeutics during the second quarter worth about $140,343,000. Summit Partners Public Asset Management LLC increased its holdings in shares of Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after acquiring an additional 354,525 shares during the period. First Light Asset Management LLC increased its holdings in shares of Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after acquiring an additional 271,617 shares during the period. Primecap Management Co. CA bought a new stake in Palvella Therapeutics in the 2nd quarter valued at about $39,150,000. Finally, Jennison Associates LLC lifted its position in Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after purchasing an additional 253,128 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.